Clinical Trials Logo

Esophageal Cancer, Squamous Cell clinical trials

View clinical trials related to Esophageal Cancer, Squamous Cell.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03301454 Recruiting - Clinical trials for Esophageal Cancer, Squamous Cell

Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer

E-DIS2
Start date: September 2018
Phase: Phase 2
Study type: Interventional

Phase II study, randomized, open-label, multicentric, willing to establish the benefit of pursuing chemotherapy beyond 6 weeks for non progressive patients. The study will proceed in two successive phases : - non randomized phase in which all patients will undergo chemotherapy - second phase in which only non progressive patients are going to be randomized ("discontinuation design"). Patients that will show progression in their disease during the first 6 weeks will be released of the study

NCT ID: NCT03126708 Recruiting - Chemotherapy Effect Clinical Trials

Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Start date: April 10, 2017
Phase: Phase 2
Study type: Interventional

This is an open-label, randomized, controlled trial. At the end of a 28-day screening period, all eligible subjects will be randomly assigned into treatment Arm A or B in a 1:1 ratio. Subjects in Arm A will receive a maximum of 6 cycles of chemotherapy (cisplatin plus paclitaxel) and cetuximab weekly in the absence of progressive disease (PD), as assessed by the Investigator, and unacceptable toxicity. After 6 cycles of treatment, subjects who derive clinical benefit will continue treatment with cetuximab as monotherapy until either PD or unacceptable toxicity. Subjects in Arm B will receive the same chemotherapy regimen as Arm A alone for a maximum of 6 cycles in the absence of PD and unacceptable toxicity.